Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Medifast Inc filings on SEC EDGAR ↗
Medifast reported a significant decline in revenue to $72.0 million for Q3 2026 compared to $89.4 million in the prior year period, resulting in a net loss of $17.5 million. The company's financial position was impacted by increased selling, general, and administrative expenses and a substantial non-cash restructuring charge of $10.8 million during the first nine months of the year.
Medifast reported Q3 2026 revenue of $72.0 million, a 19.4% decrease year-over-year, primarily due to a 47.7% decline in active earning coaches. The company posted a net loss of $17.5 million as it continues to execute its '3.0 strategy' focused on metabolic health and GLP-1 medication support. Management highlighted improved coach productivity and expects to return to profitability in the fourth quarter.
Term
Q3 2026
“The third quarter was about execution. With Trilivy now live, Reset Fuelings in our coaches’ hands, and our new compensation plan and Coach Hub launched, the major pieces of our 3.0 strategy are now in market. Revenue came in line with our guidance, and coach productivity improved year-over-year for the fourth consecutive quarter. Those are the kinds of indicators that have historically come before coach growth and revenue growth.”
Nick Johnson, Medifast's Chief Executive Officer
“The world is facing an unprecedented metabolic health crisis, and medication alone will not solve it. Lasting health requires lasting habits, and that is exactly what we were built to deliver. With nutritionally optimized products continually enhanced by research-backed ingredients that target metabolic health, and the proven power of coaching and our community, no one is better positioned to lead the way.”
Dr. Wayne Scott Andersen, Founder of the Mission, Independent Trilivy Coach
Medifast Insider Daniel R. Chard Sells $226K of Stock
Daniel R. Chard sold 19,089 shares of Medifast Inc at $11.73 to $11.98 a share (average $11.85) in 2 transactions, worth $226K in total between Sep 28, 2026 and Sep 29, 2026. Shares held after the trade: 130,609 (-6.8%).